HIV associated nephropathy cost-effectiveness of therapy
HIV associated nephropathy Microchapters |
Differentiating HIV associated nephropathy from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
HIV associated nephropathy cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of HIV associated nephropathy cost-effectiveness of therapy |
FDA on HIV associated nephropathy cost-effectiveness of therapy |
CDC on HIV associated nephropathy cost-effectiveness of therapy |
HIV associated nephropathy cost-effectiveness of therapy in the news |
Blogs on HIV associated nephropathy cost-effectiveness of therapy |
Risk calculators and risk factors for HIV associated nephropathy cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
The World Health Organization (WHO) data on HIV/AIDS for 2018 is 37.9 million people living with HIV/AIDS worldwide and 770 000 deaths due to HIV-related illnesses worldwide.[1] There is insufficient information about the cost-effectiveness of therapy in HIV associated nephropathy.
Cost-effectiveness of Therapy
- There is insufficient information about the cost-effectiveness of therapy in HIV associated nephropathy.
- The World Health Organization (WHO) data on HIV/AIDS is as the following for 2018:[1]
- People living with HIV/AIDS: 37.9 million people living with HIV/AIDS worldwide in 2018
- Mortality: 770,000 people died of HIV-related illnesses worldwide in 2018